Platelet Transfusions and Bleeding Complications Associated with Plasma Exchange Catheter Placement in Patients with Presumed Thrombotic Thrombocytopenic Purpura

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 1162-1162
Author(s):  
Steven M. Duffy ◽  
Thomas Coyle

Abstract Abstract 1162 Introduction: Since the advent of plasma exchange, mortality from thrombotic thrombocytopenic purpura (TTP) has gone from approximately 90% to less than 20%. However, due to thrombocytopenia, placement of a central venous catheter for plasma exchange can cause concern on the part of the proceduralist. Traditional teaching has been that platelet transfusion is contraindicated in TTP unless there is severe bleeding. However, a more recent review shows that the evidence for harm from platelet transfusion is uncertain. Due to the risk of bleeding, proceduralists often ask for platelet transfusion before catheter insertion. We conducted a review in our institution of bleeding episodes after cathether insertion in patients with suspected TTP. Methods: A single institution retrospective review was performed at SUNY Upstate Medical University on patients with presumed TTP from January 1999 until July of 2011. Patients were identified using both pheresis records and diagnosis codes of admitted patients in order to ensure that patients with catastrophic bleeding episodes prior to plasma exchange were not omitted. Each event was defined as placement of a pheresis catheter in a patient who presented with presumed TTP. Data was collected on patient age, platelet count prior to line insertion, the service performing the insertion, use of image guidance, bleeding complications, and survival. Results: There were 55 patients with a total of 57 catheter insertion attempts in thrombocytopenic patients with presumed TTP. One patient had an unsuccessful insertion attempt and another had catheter malfunction; both required a second insertion attempt while thrombocytopenic. Overall there were no major bleeding complications and no bleeding that required invasive intervention or removal of the catheter. There were 3 episodes of bleeding that resolved with pressure. Otherwise, there was minor bleeding that did not require any intervention documented in 14 cases. These included oozing, saturation of dressing, and 6 hematomas which did not require treatment. There was a single unsuccessful attempt at blind catheter placement which resulted in a hematoma. The median platelet count on catheter insertion was 26K with a range from 3K to 128K. Platelet transfusion was given prior to catheter placement in 14 of the episodes. The median platelet count in this population was 12K before transfusion. 5 of these 14 patients had minor bleeding complications (35%). In the 43 attempts in patients who did not receive platelet transfusion prior to line insertion, the median platelet count was 25K. 12 of these patients had minor bleeding (28%). All 3 patients with minor bleeding which required noninvasive intervention were in this group. Of the 57 attempts at line insertion, 32 were in the femoral vein, 23 in the internal jugular vein and 2 in the subclavian vein. Image guidance was used in 25 of the 57 attempts. Of the bleeding episodes that required noninvasive intervention, 2 occurred after blind placement of the catheter and 1 was after image guidance was used. Of the 55 patients treated for presumed TTP, 8 died during admission (15%). Mortality in the group of patients receiving platelet transfusion prior to catheter placement was 43% versus 5% in the patients without platelet transfusion beforehand. When adjusted for 4 patients with other causes for their thrombotic microangiopathy, the mortality in the transfused group was 40%. In general, patients receiving platelet transfusion prior to catheter insertion seemed more acutely ill, including 1 patient with HIV and pancreatitis, 1 patient with HIV, and 1 patient with pancreatitis alone. Conclusion: In this single institution retrospective review there were no major bleeding complications associated with plasma exchange catheter insertion in thrombocytopenic patients with presumed TTP. In light of the uncertain risk of platelet transfusion in patients with TTP, it is reasonable to forgo prophylactic platelet transfusion prior to catheter placement. Disclosures: No relevant conflicts of interest to declare.

2021 ◽  
Author(s):  
Virginia Zarama ◽  
Jorge A. Revelo-Noguera ◽  
Jaime A. Quintero ◽  
Ramiro Manzano ◽  
Francisco L. Uribe-Buriticá ◽  
...  

Abstract Purpose: To study the occurrence of bleeding complications in patients with severe thrombocytopenia (platelet count <20x103/µL) subjected to ultrasound-guided central venous access (UG-CVA) while receiving or not routine prophylactic platelet transfusion (PPLT).Research Question: What is the frequency of bleeding complications related to the placement of ultrasound-guided central venous access in patients with severe thrombocytopenia between 2011 and 2019 at high complexity hospital?Methods: A total of 221 patients with severe thrombocytopenia subjected to UG-CVA from January 2.011 to November 2.019 were selected. They were classified as positive (P-PPLT) or negative (N-PPLT) recipients of PPLT. Then, P-PPLT (n=72) were 1:1 propensity matched to N-PPLT based on catheter diameter, anatomical insertion site, presence of hematologic malignancy, absolute platelet count and whether the health care provider performing the procedure was an attending or a trainee. Bleeding complications were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) score and adapted to central venous catheter placement. A logistic regression analysis was then performed using “bleeding complications” as a binary compound outcome of major (Grades 3-4) and minor bleeding (Grades 1-2) vs. no bleeding.Results: Seventy-two patients were classified as P-PPLT, while 149 as N-PPLT. No grades 3-4 of bleeding events were identified in the entire population. No significant differences were observed between N-PPLT and P-PPLT for bleeding Grades 1-2 in both pre-matched (53[35.5%] vs. 26[36.1%], p=0.90) and propensity-matched populations (27[37.5%] vs. 26[36.1%], p=0.80). Logistic regression demonstrated that PPLT did not influence any bleeding complication (OR 0.9, 95%CI 0.42-1.92, p=0.791)Conclusions: Bleeding complications related to central venous catheterization in acutely ill patients with severe thrombocytopenia are not influenced by routine prophylactic platelet transfusion when catheter placement is performed under ultrasound guidance.


Transfusion ◽  
2015 ◽  
Vol 55 (7) ◽  
pp. 1798-1802 ◽  
Author(s):  
Etienne Riviere ◽  
Mélanie Saint-Léger ◽  
Chloé James ◽  
Yahsou Delmas ◽  
Benjamin Clouzeau ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3518-3518
Author(s):  
Jennifer Anadio ◽  
Adam Lane ◽  
Cristina Tarango ◽  
Peter Sturm ◽  
Joseph S. Palumbo

Abstract Preoperative screening for bleeding disorders in pediatric patients is problematic due to children's limited exposures to significant hemostatic challenges and the inherent difficulty in obtaining blood samples from young patients. Overcoming these challenges is of particular importance for surgical procedures that carry a significant bleeding risk, such as spinal surgeries. Many pediatric surgeons, including the Pediatric Orthopedic team at our Institution, rely on an unfocused history and measurement of general markers of hemostasis for preoperative screening. In order to improve preoperative screening of pediatric patients undergoing spinal procedures, we instituted the use of a detailed semi-quantitative questionnaire based on the ISTH Bleeding Assessment Tool (BAT), in combination with evaluation of PT, aPTT, platelet count, and PFA. The BAT gives positive points for a personal or family history of bleeding, and negative points for significant hemostatic challenges that did not result in bleeding complications. It was decided a priori that a BAT score of ≥3 would result in referral to Pediatric Hematology. A total of 212 patients presenting for major spinal surgeries (e.g., spinal fusion, growth rod placement) ranging in age from 3 to 25 years were prospectively evaluated in this fashion. A total of 41 patients (19.3%) had a prolongation of the PT and/or aPTT, none of which had a high BAT score. The majority of the abnormal PT/aPTT values were minimal prolongations that were not reproducible on repeat testing. Prolongation of the PT and/or aPTT revealed 3 patients with mild deficiencies of either factors VII, X, or XI, none of which were felt to be clinically significant. Prolonged PFAs were observed in 32 patients (16%), 1 of which was diagnosed with type I VWD (BAT score = 1), and the other with "possible VWD" based on a borderline VWF antigen level (BAT score = 0). Both were treated with Humate P. The remainder of the patients with a prolonged PFA were determined not to have a significant bleeding disorder after further testing. A total of 15 patients were referred to Hematology based on a high BAT score. Of these, 2 had a history of thrombocytopenia (1 with known DiGeorge syndrome and 1 with Depakote-related thrombocytopenia). Neither required platelet transfusion. One patient with a high BAT score was known to have type I VWD and was treated with Humate P, another was diagnosed with low expression of glycoprotein GP1b and was treated with Humate P and platelet transfusion. The remainder of the patients with high BAT scores were not felt to have a clinically significant bleeding disorder based on a Hematologist's assessment. None of the 212 patients evaluated were felt to have excessive intraoperative bleeding by the surgical team, suggesting that none of the patients had a significant undiagnosed hemostatic defect. Together, these results suggest that reliance on history or screening labs alone may not be sufficient for many pediatric surgery patients. While the PFA identified 2 patients with mild/possible VWD that would have been missed by the BAT, the PFA also had a significant number of apparent false positives. The combination of a BAT and a platelet count, as well as assessment of VWF activity for patients without previous hemostatic system challenges, may provide a more effective screening methodology for institutions with ready access to VWF activity measurement. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4293-4293
Author(s):  
Lakshminarayanan Nandagopal ◽  
Muthu Veeraputhiran ◽  
Tania Jain ◽  
Ayman Soubani ◽  
Charles A. Schiffer

Abstract Introduction Prophylactic platelet transfusions are often performed prior to bronchoscopy or broncho-alveolar lavage (BAL) to prevent bleeding in thrombocytopenic patients. There is a paucity of data to validate this approach, with a platelet transfusion threshold of <50,000/mm3 largely based on expert opinion. We conducted a retrospective study on the incidence of bleeding complications in thrombocytopenic patients undergoing bronchoscopy. Methods We identified 150 consecutive patients with platelet counts <100,000/mm3 who underwent bronchoscopy and/or BAL from January 2009 to May 2014 at our institution. Bronchoscopies performed in patients with frank hemoptysis and trans-bronchial lung biopsy procedures were excluded. Patient characteristics, underlying diagnosis, platelet count prior to bronchoscopy, administration of platelet transfusions and bronchoscopy details were recorded. Factors affecting bleeding risk including presence of renal dysfunction (defined as BUN >30 and/or Cr>2.0) and coagulation studies (PT, PTT, INR) were identified. The British Thoracic Society guidelines1 were used to categorize bleeding as a result of bronchoscopy. Data were analyzed using descriptive statistics. Results The median age was 59 years (range 27-90), with two-thirds of patients (63%) being male. One hundred and seventeen (78%) patients had underlying malignancy and 55 (37%) had thrombocytopenia related to malignancy. Fellows and residents under the supervision of a bronchoscopy certified attending performed all but 4 of the bronchoscopies. Infection (40%) was the primary indication for bronchoscopy with BAL performed in 127 (85%) patients. Fifty-eight of 89 (65%) patients with baseline platelet counts <50,000/mm3 received prophylactic transfusions compared to 8% of those with platelet counts >50,000/mm3. The platelet count did not rise to >50,000//mm3 in many transfused patients. Seventy patients (47%) had counts <50,000/mm3 and eighty patients (53%) had counts >50,000/mm3 at the time of bronchoscopy. 49% were receiving immunosuppressive medications, 45% had renal dysfunction and 8% had INR >1.5. Bloody lavage that resolved spontaneously without continuous suctioning (Grade 0) was observed in 9 (6%) patients. Bleeding that required continuous suctioning but then resolved spontaneously (Grade 1) was noted in 1 patient with a platelet count of 61,000/mm3. Of 10 total bleeding events, 7 occurred in patients who were intubated. Two additional patients with platelet counts of 30,000/mm3 and 53,000/mm3 had diffuse alveolar hemorrhage, which was present before bronchoscopy. “Old” blood and blood clots were observed in 6 patients. Discussion The low incidence of bleeding complications from bronchoscopy +/- BAL even in patients with platelet counts <30,000/mm3 (3 episodes in 31 patients, all grade 0) demonstrates that bronchoscopy can be safely done in severely thrombocytopenic patients. Adopting a lower threshold for prophylactic transfusions could save a considerable number of platelet units and translate into significant cost savings and decreased risk of transfusion-related complications. Table 1 Platelet count, transfusion history and bleeding complications during bronchoscopy Platelet count at the time of bronchoscopy Number (n) and percentage (%) of patients who underwent bronchoscopy Number of patients who received prior platelet transfusion Bleeding during bronchoscopy n % 0-15,000/mm3 9 6% (9/150) 5 Grade 0=1 pt 16-29 22 15% 16 Grade 0=2 pts 30-39 17 11% 9 Grade 0=1 pt 40-49 22 15% 9 Grade 0=3 pts 50-75 44 29% 14 Grade 1=1 pt 76-100 36 24% 10 Grade 0=2 pts Total 150 63 Grade 0=9 pts, Grade 1=1 pt. 1.Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013:68 Suppl 1:i1-i44 Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 962-962
Author(s):  
Jean-Louis H. Kerkhoffs ◽  
Rinie J. van Wordragen-Vlaswinkel ◽  
Jeroen C.J. Eikenboom ◽  
Anneke Brand

Abstract Introduction: Central venous catheters are frequently used in hematooncological patients for the administration of chemotherapy, antibiotics and parenteral feeding. Despite low platelet counts, observed in this category of patients, catheter related thrombosis (VTE), with the need for anticoagulant therapy, still occurs in 9.7% of the patients. Treatment of this complication in our institute consists of the removal of the catheter and anti-coagulant therapy, consisting of conventional heparin or low molecular weight heparin. Although solely based on expert opinion, the generally accepted platelet transfusion threshold of 10 x 109/l is raised to 20 – 40 x 109/l. In our institute a trigger of 30 x 109/l is used. We investigated whether this trigger policy is effective in the prevention of bleeding complications. Methods: We performed a case-control study to study bleeding complications and threshold policy. From 1 February 2000 to 1 May 2005 we reviewed medical records of patients, admitted at the hematology department of the Leiden University Medical Center. A total of 22 patients were identified having thrombosis confirmed by ultrasound or phlebography. The database of a recently performed clinical trial in our institution was used to select a control group. Thirty-one controls were selected, matched for age, gender, diagnosis and treatment. For each patient, we calculated the days at risk of bleeding, i.e. days of thrombocytopenia with or without anti-coagulant therapy and recorded bleeding complications, platelet and red cell transfusions from the medical charts. Statistical analysis was performed using SPSS. Results: There were no significant differences between patients with or without VTE in regard to age, gender, diagnosis and treatment. The number of days at risk of bleeding for patients without VTE was 511 days and for VTE group 239 days. The table shows the number of bleeding complications, the mean platelet count, the mean platelet transfusion threshold and the number of platelet and red cell transfusions. Both univariate as multivariate analysis (including age, gender, diagnosis, treatment and VTE-status) showed a significant effect of the existence of VTE on the occurrence of bleeding complications. The Odds’ ratio of bleeding in the VTE group compared to the non-VTE group was 2.9 (CI 95: 1.7 – 5.0; p = 0.0002). More then 95% of the bleeding complications consisted of WHO grades I and II. No lethal bleeding was observed. Discussion: Patients experiencing (catheter-related) venous thrombosis treated with anticoagulant therapy during a period of thrombocytopenia showed an increased risk of bleeding complications, despite a higher platelet transfusion threshold. Whether steering between Scylla and Charibdis can be facilitated by raising the platelet transfusion threshold remains to established. Study outcome No VTE VTE p value n = number Days at risk 511 239 n bleeding complications per day at risk 0.05 0.13 0.0002 mean platelet count (10E9/l) +/− SD 28 +/− 16 38 +/− 17 &lt; 0.0001 mean platelet transfusion threshold (10E9/l) +/− SD 12 +/− 9 28 +/− 12 &lt; 0.0001 n platelet transfusions per day at risk 0.35 0.49 0.0003 n red cell transfusions per day at risk 0.34 0.41 0.073


1975 ◽  
Vol 9 (10) ◽  
pp. 560-565
Author(s):  
Robert J. Ignoffo

The incidence of bleeding from heparin therapy in patients with diagnosed pulmonary embolism and deep vein thrombosis was evaluated in a university hospital. Major or minor bleeding episodes occurred in 32 percent of patients and of these 50 percent were major episodes requiring cessation of therapy and blood transfusion. Activated clotting times were not excessively prolonged during bleeding episodes nor was there any apparent association with the age or sex of the patient. It is felt that bleeding secondary to intermittent intravenous heparin therapy may be the result of the high degree of clotting inhibition from 15 minutes to 2 hours after injection. It is suggested that continuous intravenous infusion of heparin is as effective as intermittent heparin injections and yet appears to produce a lower incidence of both major and minor bleeding episodes.


2021 ◽  
Vol 73 (1) ◽  
Author(s):  
Arash Hashemi ◽  
Fady Gerges ◽  
Haseeb Raza Naqvi ◽  
Irina Kotlar ◽  
Sara Moscatelli ◽  
...  

Abstract Background Novel coronavirus disease 2019 (COVID-19) is known to lead not only to severe acute respiratory syndrome, but also can result in thromboembolic events in both the venous and the arterial circulation by inducing coagulation disorders. The potential causes of coagulopathy are inflammation, platelet activation, endothelial dysfunction, and stasis. The thrombotic events including pulmonary embolism, deep venous thrombosis as well as intracatheter thrombosis are more likely to develop in patients infected with severe form of SARS-CoV-2 who are admitted to ICU. Furthermore, these events contribute to multi-organ failure. Case presentation Herein, we report a case of an immunocompromised COVID-19 elderly patient with acute lymphocytic leukemia who developed myocardial infarction with ST elevation in the setting of acute pulmonary thromboembolism in the presence of zero platelet count. Despite successful urgent coronary revascularization and platelet transfusion, the patient eventually died after failed resuscitation efforts. Conclusion Patients with COVID-19 infection are at a greater risk of developing cardiovascular complications, but their appropriate management can decrease the risk of fatal events. Coronary thrombosis associated with pulmonary thromboembolism in the setting of thrombocytopenia is a rare and a complex to manage condition. Significance of single antiplatelet agent in STEMI with thrombocytopenia merits further studies. According to expert opinions and literature reviews, we must avoid dual antiplatelet therapy in these patients and keep platelet transfusion as a standard therapy to avoid drastic bleeding complications.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3976-3976
Author(s):  
Shakira Jeanene Grant ◽  
Patricia Ford ◽  
Rosemarie Mick ◽  
Gina Keck

Abstract INTRODUCTION High dose chemotherapy (HDC) followed by Autologous stem cell transplant (ASCT) has been shown to provide curative benefit in patients with relapsed lymphoma and multiple myeloma, often times requiring hematopoietic support until marrow engraftment. Due to Jehovah's Witnesses (JW), refusal of blood products treatment challenges arise. This prospective study represents 125 JW with lymphoma (n= 55), multiple myeloma (MM) (n= 68) or amyloidosis (n=2), treated with HDC and ASCT without transfusions. PATIENTS AND METHODS All patients with diagnoses of MM and lymphoma were considered eligible for enrollment, irrespective of prior regimens or complete remissions. Patients were primed pre-transplant with intravenous iron and erythropoietin at a dose of 60,000 units weekly. Cytokine mobilization of stem cells was used preferentially over chemo-mobilization to facilitate apheresis. HDC post apheresis was delayed until hemoglobin (Hb) and platelets approached 11g/dl and 100 x 103/ μL respectively. All patients with multiple myeloma received standard dose Melphalan 200mg/m2, with dose adjustment to 140-150mg/m2 in patients with severe kidney dysfunction. Lymphoma patients received BCNU 300mg/m2 on day 1, Cyclophosphamide 1500mg/m2 day 2-5, and VP16 700mg/m2/day on days 2-4. Post-transplant, blood management techniques included minimization of unnecessary phlebotomy, limitation of potential sources of blood loss, namely from the gastrointestinal tract, by the utilization of proton pump inhibitors and stool softeners and avoidance of antiplatelet agents wherever possible. In menstruating females progestational agents were given to cease menstrual flow. All patients received granulocyte colony stimulating factor (G-CSF) and erythropoietin. Thrombocytopenia was managed with the antifibrinolytic agent aminocaproic acid, phythonadione and rarely cryoprecipitate. RESULTS Ninety percent of patients (n=113) were alive at 100 days post transplantation, and 12 patients had died prior to 100 days. Six patients (4.8%) died prior to day 30 and were considered transplant-related mortalities (TRMs). The etiologies were as follows: profound anemia (n=1), severe sepsis (n=1), multi-organ failure due to pancytopenia (n=1) or cardiac events (n=3). Since March 2010 there have been no additional TRMs. There were 2 life threatening (grade 3 – 4) but non-fatal bleeding complications, 2 grade 2 bleeding complications and minor bleeding (grade 1) in 15 patients. The median decrease in Hb was 5.0 g/dL (range 0-10) for all patients, with a median Hb nadir of 7.0 g/dL. The median total number of days with a platelet count < 10 x 103/μL was 3 days (range 0–14) with a median platelet nadir of 5.0 x 103/μL. Cardiac complications occurred in 40 patients (32%), most commonly arrhythmias (n=23). CONCLUSION ASCT can safely be performed without transfusion support in JWs with acceptable bleeding complications. Though demonstrating a TRM which is higher than that of the national average this appears acceptable for this unique patient population. Furthermore the bloodless approach may be appropriate in a select patient population undergoing HDC followed by ASCT, an approach which would reduce blood transfusion and its associated complications through the utilization of techniques and alternatives such as erythropoietin, aminocaproic acid, phytonadione and iron. Additionally the absence of bleeding complications at platelet counts > 5 x 103/μL, suggest use of a prophylactic platelet transfusion trigger of ≥ 5 x 103/μL, may be appropriate in select patients. Table 1. Engraftment Parameters No. Median Range Neutrophils Days to ANC ≥1,000/mL 125 10 4 - 19 Hemoglobin Hemoglobin at onset of conditioning, g/dL 125 11.8 7.0 – 11.8 Hemoglobin decrease to nadir, g/dL 124 4.9 0.5 – 10.2 Hemoglobin nadir, g/dL 123 7.0 2.0 – 11.6 Duration of grade 3/4 anemia hemoglobin < 8 g/dL 125 9 1 - 28 Hemoglobin at day +30, g/dL 98 10.9 3.5 – 14.9 Platelets Platelets at onset of conditioning, /mL 124 148 65 - 502 Platelet nadir, /mL 123 5 1 - 50 Duration of Grade 4 thrombocytopenia platelets <10x103/μL 125 3 0 - 14 Duration of Grade 3 thrombocytopenia platelets <20x103/mL Days to platelets > 20,000/µL 125 125 4 11 0 – 20 0 - 23 Platelet count at day + 30, /mL 97 137 17 - 557 Disclosures No relevant conflicts of interest to declare.


1981 ◽  
Author(s):  
M Hellaren ◽  
F Nygârds

Twenty women were treated with i.v./s.c. heparin during pregnancy because of acute thromboembolic complications (T-E) and 15 were given s.c. heparin as prophylaxis because of earlier T-E. All women injected themselves without problems. Minor allergic reactions disappeared when preservative was avoided. The therapeutic treatment was adjusted to 1.5-2 times prolongation of APTT and the prophylaxis was decided sufficient if 5-10 secs, prolongation of APTT was registered 3-4 hours postinjection. Twenty five pregnancies were uncomplicated. Six pregnancies were connected with various obstetric complications and 5 with minor bleeding complications such as wound and vaginal hematomas. Eight pregnancies were complicated by incipient prematur labour. No rethrombosis occurred in the prophylactic group but 5 of the 20 women in the therapeutic group had rethrombosis before prophylaxis had started. All children were in good health but one had low birth weight for gestational age.The level of antithrombin (AT) and platelet count were studied in 16 women and liver function was registered in 13 of them. The level of AT decreased to a mean of 55%, measured by chromogenic substrate S-2238, after 2-4 weeks s.c. therapy in the prophylactic group. In the therapeutic group an expected mean decrease to maximum 56% was noted initially during i.v./s.c. heparin treatment. In both groups the level of AT normalized during continued heparin treatment. After finished treatment all women had normal level of AT. Platelet count and liverfunction were mainly unchanged.These regimes seem adequate during pregnancy but AT ought to be analysed in order to avoid increased risk for T-E if heparin must be withdrawn or decreased. Examination for incipient prematur labour should probably be more intensive in these groups of pregnant women.


Sign in / Sign up

Export Citation Format

Share Document